An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2021.12.15.472828: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication Contamination: All cells routinely tested negative for mycoplasma using a PCR-based assay. Table 2: Resources
Antibodies Sentences Resources Monoclonal antibody purification: The mAbs used in this paper (COV2-2196, COV2-2130, S309, REGN10933, REGN10987, LY-CoV555, LY-CoV016, CT-P59, SARS2-38) have been described previously12,15,19,42-46. COV2-2130suggested: NoneSARS2-38suggested: NoneAntibody-virus complexes were added to Vero-TMPRSS2 or Vero-hACE2-TMPRSS2 cell monolayers in 96-well plates and incubated at 37°C for 1 h. Vero-TMPRSS2suggested: NonePla… SciScore for 10.1101/2021.12.15.472828: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication Contamination: All cells routinely tested negative for mycoplasma using a PCR-based assay. Table 2: Resources
Antibodies Sentences Resources Monoclonal antibody purification: The mAbs used in this paper (COV2-2196, COV2-2130, S309, REGN10933, REGN10987, LY-CoV555, LY-CoV016, CT-P59, SARS2-38) have been described previously12,15,19,42-46. COV2-2130suggested: NoneSARS2-38suggested: NoneAntibody-virus complexes were added to Vero-TMPRSS2 or Vero-hACE2-TMPRSS2 cell monolayers in 96-well plates and incubated at 37°C for 1 h. Vero-TMPRSS2suggested: NonePlates with WA1/2020 D614G were washed and sequentially incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57, and SARS2-7147 anti-S antibodies. SARS2-57suggested: NoneSARS2-7147suggested: Noneanti-Ssuggested: NoneExperimental Models: Cell Lines Sentences Resources Cells: Vero-TMPRSS239 and Vero-hACE2-TMPRRS26 cells were cultured at 37°C in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10LmM HEPES pH 7.3, and 100LU/ml of penicillin–streptomycin. Vero-hACE2-TMPRRS26suggested: NoneVero-hACE2-TMPRSS2 cells were supplemented with 10 µg/mL of puromycin. Vero-hACE2-TMPRSS2suggested: NoneThe B.1.1.529 isolate (hCoV-19/USA/WI-WSLH-221686/2021) was obtained from a midturbinate nasal swab and passaged once on Vero-TMPRSS2 cells as described41. Vero-TMPRSS2suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)Software and Algorithms Sentences Resources Antibody-dose response curves were analyzed using non-linear regression analysis with a variable slope (GraphPad Software), and the half-maximal inhibitory concentration (EC50) was calculated. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 19. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
